comparison of glp-1 drugs GLP-1 Medications: A Quick Comparison Understanding Weight Loss Medications: GLP-1
Description
Learn what the evidence shows about muscle symptoms with semaglutide, tirzepatide, and other GLP-1 medications, plus when to contact your doctor and how to protect muscle mass during treatment.
Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)
Diabetic patients prescribed tirzepatide, semaglutide, dulaglutide, and exenatide are less likely to be diagnosed with depression after starting the medication compared to those not on a glucagon-like peptide-1 receptor agonist (GLP-1) medication.
Observational studies in autoimmune rheumatic diseases (ARDs) such as rheumatoid arthritis and systemic lupus erythematosus indicate
Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)
But from 2030, Pfizer could emerge as a credible Top-3 obesity player if both the injectable and oral combo strategies succeed
